GI
ALNY icon

GAMMA Investing’s Alnylam Pharmaceuticals ALNY Stock Holding History

GAMMA Investing’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$282K Sell
937
-57
-6% -$17.2K 0.01% 1020
2026
Q1 		$329K Buy
994
+101
+11% +$34.4K 0.02% 795
2025
Q4 		$355K Buy
893
+70
+9% +$31K 0.02% 677
2025
Q3 		$375K Buy
823
+97
+13% +$39.5K 0.02% 610
2025
Q2 		$237K Buy
726
+110
+18% +$30.4K 0.02% 803
2025
Q1 		$166K Buy
616
+77
+14% +$19.8K 0.01% 874
2024
Q4 		$127K Sell
539
-15
-3% -$3.94K 0.01% 945
2024
Q3 		$152K Buy
554
+138
+33% +$35.9K 0.02% 750
2024
Q2 		$101K Buy
416
+205
+97% +$32.4K 0.01% 775
2024
Q1 		$31.5K Sell
211
-59
-22% -$9.84K 0.01% 1331
2023
Q4 		$46.7K Buy
+270
New +$46K 0.01% 932

Other funds holding ALNY

CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
MIF
Mediolanum International Funds Dublin 1, Ireland $11.7B AUM 47.18% 1-Year Est. Return
SSA
Sierra Summit Advisors Incline Village, Nevada $895M AUM 106% 1-Year Est. Return
FISPB
Fideuram - Intesa Sanpaolo Private Banking Turin $3.33B AUM
OIAM
OFI Invest Asset Management Paris, France $10B AUM 48.47% 1-Year Est. Return

GAMMA Investing's ALNY Position: Q2 2026 in Review

GAMMA Investing reduced its Alnylam Pharmaceuticals (ALNY) stake by 5.7% in Q2 2026, selling an estimated $17.2K and leaving 937 shares worth $282K. The position accounts for 0.01% of the portfolio, ranked #1020.

GAMMA Investing first reported a position in ALNY in Q4 2023 and has held it in 11 quarters since. The position peaked at $375K in Q3 2025. 136 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • GAMMA Investing held 937 shares of Alnylam Pharmaceuticals worth $282K as of Q2 2026.
  • GAMMA Investing sold 57 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $17.2K.
  • Alnylam Pharmaceuticals made up 0.01% of GAMMA Investing's portfolio in Q2 2026, its #1020 holding.
  • GAMMA Investing first reported a position in Alnylam Pharmaceuticals in Q4 2023 and has held it in 11 quarters since.
  • GAMMA Investing's Alnylam Pharmaceuticals position peaked at $375K in Q3 2025.
  • 136 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on GAMMA Investing's 13F filing for Q2 2026, filed 7 Jul 2026.